Archive - February 2019
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor
Zogenix Submits New Drug Application to U.S. Food & Drug Administration for Fintepla for the Treatment of Dravet Syndrome
FDA Advisory Committee Recommends Approval of Spravato (esketamine) Nasal Spray for Adults with Treatment-Resistant Depression
Keytruda combo outshines Opdivo in kidney cancer
Bicycle Therapeutics to tackle AMR with government funding
FDA panel backs J&J’s new-class antidepressant
Medicinal cannabis firm Althea enters UK market
Spravato gets FDA Advisory Committee approval